Clinical Trial

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris
Protocol Amendment History 30 amendments
This ClinicalTrials.gov record has been amended 30 times since 2020-06-05; most recent amendment 2026-05-28.
Status change: Not Yet Recruiting → Recruiting 2020-06-29
Trial Details
NCT Number NCT04422912
Lead Sponsor Cabaletta Bio
Conditions Pemphigus Vulgaris
Enrollment 40 participants
Start Date 2020-09-29
Primary Completion 2029-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-29